{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:57:47Z","timestamp":1793750267259,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,14]]},"DOI":"10.7759\/cureus.71408","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T07:22:45Z","timestamp":1728890565000},"source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Biologic Therapies in the Management of Allergic Rhinitis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Ibtihal","family":"Yamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khulud","family":"Bu Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjaad","family":"Alsulami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salam","family":"Sait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz H","family":"Althumali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28501","article-title":"Allergic rhinitis and treatment modalities: a review of literature","volume":"14","author":"Sharma K","year":"2022","unstructured":"Sharma K, Akre S, Chakole S, Wanjari MB. Allergic rhinitis and treatment modalities: a review of literature. Cureus. 2022, 14:28501. 10.7759\/cureus.28501","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2014-306300","article-title":"Optimal management of allergic rhinitis","volume":"100","author":"Scadding GK","year":"2015","unstructured":"Scadding GK. Optimal management of allergic rhinitis. Arch Dis Child. 2015, 100:576-82. 10.1136\/archdischild-2014-306300","journal-title":"Arch Dis Child"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S291747","article-title":"Allergic rhinitis therapy decisions during a routine consultation: a multicenter, cross-sectional survey","volume":"14","author":"G\u00e1lffy G","year":"2021","unstructured":"G\u00e1lffy G, Emmeluth M, Koltun A, Kopietz F, Nguyen DT, Kuhl HC. Allergic rhinitis therapy decisions during a routine consultation: a multicenter, cross-sectional survey. J Asthma Allergy. 2021, 14:335-45. 10.2147\/JAA.S291747","journal-title":"J Asthma Allergy"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-018-0314-1","article-title":"The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option","volume":"15","author":"Bjermer L","year":"2019","unstructured":"Bjermer L, Westman M, Holmstr\u00f6m M, Wickman MC. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. Allergy Asthma Clin Immunol. 2019, 15:24. 10.1186\/s13223-018-0314-1","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01344-4","article-title":"Pathogenesis of allergic diseases and implications for therapeutic interventions","volume":"8","author":"Wang J","year":"2023","unstructured":"Wang J, Zhou Y, Zhang H, et al.. Pathogenesis of allergic diseases and implications for therapeutic interventions. Signal Transduct Target Ther. 2023, 8:138. 10.1038\/s41392-023-01344-4","journal-title":"Signal Transduct Target Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S374346","article-title":"Pharmacological management of allergic rhinitis: a consensus statement from the Malaysian Society of Allergy and Immunology","volume":"15","author":"Abdullah B","year":"2022","unstructured":"Abdullah B, Abdul Latiff AH, Manuel AM, et al.. Pharmacological management of allergic rhinitis: a consensus statement from the Malaysian Society of Allergy and Immunology. J Asthma Allergy. 2022, 15:983-1003. 10.2147\/JAA.S374346","journal-title":"J Asthma Allergy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S273478","article-title":"Self-management in allergic rhinitis: strategies, outcomes and integration into clinical care","volume":"16","author":"Ciprandi G","year":"2023","unstructured":"Ciprandi G. Self-management in allergic rhinitis: strategies, outcomes and integration into clinical care. J Asthma Allergy. 2023, 16:1087-95. 10.2147\/JAA.S273478","journal-title":"J Asthma Allergy"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020270","article-title":"Biologic therapies for asthma and allergic disease: past, present, and future","volume":"16","author":"Ram\u00edrez-Jim\u00e9nez F","year":"2023","unstructured":"Ram\u00edrez-Jim\u00e9nez F, Pav\u00f3n-Romero GF, Vel\u00e1squez-Rodr\u00edguez JM, L\u00f3pez-Garza MI, Lazarini-Ruiz JF, Guti\u00e9rrez-Quiroz KV, Teran LM. Biologic therapies for asthma and allergic disease: past, present, and future. Pharmaceuticals (Basel). 2023, 16:270. 10.3390\/ph16020270","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1729350","article-title":"Current and emerging biologic therapies for allergic rhinitis and chronic rhinosinusitis","volume":"20","author":"Licari A","year":"2020","unstructured":"Licari A, Castagnoli R, De Filippo M, Foiadelli T, Tosca MA, Marseglia GL, Ciprandi G. Current and emerging biologic therapies for allergic rhinitis and chronic rhinosinusitis. Expert Opin Biol Ther. 2020, 20:609-19. 10.1080\/14712598.2020.1729350","journal-title":"Expert Opin Biol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.53175","article-title":"Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases","volume":"54","author":"Raychaudhuri SP","year":"2009","unstructured":"Raychaudhuri SP, Raychaudhuri SK. Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases. Indian J Dermatol. 2009, 54:100-9. 10.4103\/0019-5154.53175","journal-title":"Indian J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4110\/in.2022.22.e9","article-title":"Targeted immunotherapy for autoimmune disease","volume":"22","author":"Jung SM","year":"2022","unstructured":"Jung SM, Kim WU. Targeted immunotherapy for autoimmune disease. Immune Netw. 2022, 22:9. 10.4110\/in.2022.22.e9","journal-title":"Immune Netw"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119563","article-title":"Switching biological therapies in severe asthma","volume":"24","author":"Scioscia G","year":"2023","unstructured":"Scioscia G, Nolasco S, Campisi R, et al.. Switching biological therapies in severe asthma. Int J Mol Sci. 2023, 24:9563. 10.3390\/ijms24119563","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2020.08.002","article-title":"Long-term omalizumab efficacy in allergic rhinitis","volume":"227","author":"Cavaliere C","year":"2020","unstructured":"Cavaliere C, Begvarfaj E, Incorvaia C, et al.. Long-term omalizumab efficacy in allergic rhinitis. Immunol Lett. 2020, 227:81-7. 10.1016\/j.imlet.2020.08.002","journal-title":"Immunol Lett"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S288952","article-title":"Effectiveness and response predictors of omalizumab in treating patients with seasonal allergic rhinitis: a real-world study","volume":"14","author":"Ma T","year":"2021","unstructured":"Ma T, Wang H, Wang X. Effectiveness and response predictors of omalizumab in treating patients with seasonal allergic rhinitis: a real-world study. J Asthma Allergy. 2021, 14:59-66. 10.2147\/JAA.S288952","journal-title":"J Asthma Allergy"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.23.2956","article-title":"Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial","volume":"286","author":"Casale TB","year":"2001","unstructured":"Casale TB, Condemi J, LaForce C, et al.. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001, 286:2956-67. 10.1001\/jama.286.23.2956","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2009.00900.x","article-title":"Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously","volume":"21","author":"Kamin W","year":"2010","unstructured":"Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2010, 21:160-5. 10.1111\/j.1399-3038.2009.00900.x","journal-title":"Pediatr Allergy Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100469","article-title":"Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: findings from a post-hoc analysis of a randomised phase III study","volume":"13","author":"Li J","year":"2020","unstructured":"Li J, Wang C, Liu C, et al.. Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: findings from a post-hoc analysis of a randomised phase III study. World Allergy Organ J. 2020, 13:100469. 10.1016\/j.waojou.2020.100469","journal-title":"World Allergy Organ J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.05.026","article-title":"Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis","volume":"125","author":"Busse WW","year":"2020","unstructured":"Busse WW, Maspero JF, Lu Y, et al.. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2020, 125:565-576.e1. 10.1016\/j.anai.2020.05.026","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.11.051","article-title":"Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma","volume":"142","author":"Weinstein SF","year":"2018","unstructured":"Weinstein SF, Katial R, Jayawardena S, et al.. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018, 142:171-177.e1. 10.1016\/j.jaci.2017.11.051","journal-title":"J Allergy Clin Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2004","article-title":"Pharmacokinetics and concentration-response of dupilumab in patients with seasonal allergic rhinitis","volume":"62","author":"Kamal MA","year":"2022","unstructured":"Kamal MA, Franchetti Y, Lai CH, et al.. Pharmacokinetics and concentration-response of dupilumab in patients with seasonal allergic rhinitis. J Clin Pharmacol. 2022, 62:689-95. 10.1002\/jcph.2004","journal-title":"J Clin Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-022-00171-2","article-title":"Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life","volume":"20","author":"Nettis E","year":"2022","unstructured":"Nettis E, Brussino L, Patella V, et al.. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life. Clin Mol Allergy. 2022, 20:6. 10.1186\/s12948-022-00171-2","journal-title":"Clin Mol Allergy"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.11.008","article-title":"Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy","volume":"72","author":"Nagase H","year":"2023","unstructured":"Nagase H, Suzukawa M, Oishi K, Matsunaga K. Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergol Int. 2023, 72:11-23. 10.1016\/j.alit.2022.11.008","journal-title":"Allergol Int"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0238-2023","article-title":"Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials","volume":"33","author":"Kyriakopoulos C","year":"2024","unstructured":"Kyriakopoulos C, Gogali A, Markozannes G, Kostikas K. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials. Eur Respir Rev. 2024, 33:230238. 10.1183\/16000617.0238-2023","journal-title":"Eur Respir Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.01.020","article-title":"Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a target trial emulation","volume":"151","author":"Akenroye AT","year":"2023","unstructured":"Akenroye AT, Segal JB, Zhou G, et al.. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a target trial emulation. J Allergy Clin Immunol. 2023, 151:1269-76. 10.1016\/j.jaci.2023.01.020","journal-title":"J Allergy Clin Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100787","article-title":"Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU\/mL","volume":"16","author":"Menzella F","year":"2023","unstructured":"Menzella F, Just J, Sauerbeck IS, et al.. Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU\/mL. World Allergy Organ J. 2023, 16:100787. 10.1016\/j.waojou.2023.100787","journal-title":"World Allergy Organ J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00010701","article-title":"Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases","volume":"17","author":"Bousquet J","year":"2008","unstructured":"Bousquet J, Wahn U, Meltzer EO, Fox H, Hedgecock S, Thomas K, Fowler-Taylor A. Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases. Eur Respir Rev. 2008, 17:1-9. 10.1183\/09059180.00010701","journal-title":"Eur Respir Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2018.77243","article-title":"The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry","volume":"35","author":"Hutyrov\u00e1 B","year":"2018","unstructured":"Hutyrov\u00e1 B, Bystro\u0148 J. The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry. Postepy Dermatol Alergol. 2018, 35:510-5. 10.5114\/ada.2018.77243","journal-title":"Postepy Dermatol Alergol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2024.1409342","article-title":"Omalizumab for the reduction of allergic reactions to foods: a narrative review","volume":"5","author":"Ghouri H","year":"2024","unstructured":"Ghouri H, Habib A, Nazir Z, Lohana N, Akilimali A. Omalizumab for the reduction of allergic reactions to foods: a narrative review. Front Allergy. 2024, 5:1409342. 10.3389\/falgy.2024.1409342","journal-title":"Front Allergy"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h A","year":"2020","unstructured":"Le Floc'h A, Allinne J, Nagashima K, et al.. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020, 75:1188-204. 10.1111\/all.14151","journal-title":"Allergy"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.01.002","article-title":"Dupilumab: basic aspects and applications to allergic diseases","volume":"69","author":"Matsunaga K","year":"2020","unstructured":"Matsunaga K, Katoh N, Fujieda S, Izuhara K, Oishi K. Dupilumab: basic aspects and applications to allergic diseases. Allergol Int. 2020, 69:187-96. 10.1016\/j.alit.2020.01.002","journal-title":"Allergol Int"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13091404","article-title":"Targeting IL-4 and IL-13 receptors on eosinophils in CRSwNP patients: the clinical efficacy of dupilumab","volume":"13","author":"Piazzetta GL","year":"2023","unstructured":"Piazzetta GL, Lobello N, Chiarella E, Rizzuti A, Pelaia C, Pelaia G, Lombardo N. Targeting IL-4 and IL-13 receptors on eosinophils in CRSwNP patients: the clinical efficacy of dupilumab. J Pers Med. 2023, 13:1404. 10.3390\/jpm13091404","journal-title":"J Pers Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton JD","year":"2021","unstructured":"Hamilton JD, Harel S, Swanson BN, et al.. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021, 51:915-31. 10.1111\/cea.13954","journal-title":"Clin Exp Allergy"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040634","article-title":"Dupilumab in inflammatory skin diseases: a systematic review","volume":"13","author":"Olbrich H","year":"2023","unstructured":"Olbrich H, Sadik CD, Ludwig RJ, Tha\u00e7i D, Boch K. Dupilumab in inflammatory skin diseases: a systematic review. Biomolecules. 2023, 13:634. 10.3390\/biom13040634","journal-title":"Biomolecules"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren J","year":"2020","unstructured":"Corren J, Castro M, O'Riordan T, et al.. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2020, 8:516-26. 10.1016\/j.jaip.2019.08.050","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/BF01630102","article-title":"Long-term preservation of hematopoietic tissue for marrow transplantation","volume":"28","author":"Lewis JP","year":"1974","unstructured":"Lewis JP. Long-term preservation of hematopoietic tissue for marrow transplantation. Blut. 1974, 28:389-95. 10.1007\/BF01630102","journal-title":"Blut"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/ped4.12146","article-title":"The use of biologics in children with allergic rhinitis and chronic rhinosinusitis: current updates","volume":"3","author":"Shinee T","year":"2019","unstructured":"Shinee T, Sutikno B, Abdullah B. The use of biologics in children with allergic rhinitis and chronic rhinosinusitis: current updates. Pediatr Investig. 2019, 3:165-72. 10.1002\/ped4.12146","journal-title":"Pediatr Investig"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.07.004","article-title":"A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps","volume":"123","author":"Codispoti CD","year":"2019","unstructured":"Codispoti CD, Mahdavinia M. A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps. Ann Allergy Asthma Immunol. 2019, 123:232-9. 10.1016\/j.anai.2019.07.004","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/307041-efficacy-of-biologic-therapies-in-the-management-of-allergic-rhinitis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T07:22:49Z","timestamp":1728890569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/307041-efficacy-of-biologic-therapies-in-the-management-of-allergic-rhinitis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.71408","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}